PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers.

ABSTRACT: Poly (ADP-ribose) polymerases (PARPs) play an important role in various cellular processes, such as replication, recombination, chromatin remodeling, and DNA repair. Emphasizing PARP's role in facilitating DNA repair, the PARP pathway has been a target for cancer researchers in developing compounds which selectively target cancer cells and increase sensitivity of cancer cells to other anticancer agents, but which also leave normal cells unaffected. Since certain tumors (BRCA1/2 mutants) have deficient homologous recombination repair pathways, they depend on PARP-mediated base excision repair for survival. Thus, inhibition of PARP is a promising strategy to selectively kill cancer cells by inactivating complementary DNA repair pathways. Although PARP inhibitor therapy has predominantly targ

SUBMITTER: Keung MYT 

PROVIDER: S-EPMC6517993 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature